Local Delivery Polymer Provides Sustained Antifungal Activity of Amphotericin B with Reduced Cytotoxicity

Overview

Journal Exp Biol Med (Maywood)

Specialty Biology

Date 2019 Mar 23

PMID 30897959

Citations 7

Authors

Rebecca M Haley

Sean T Zuckerman

Catherine A Gormley

Julius N Korley

Horst A von Recum

Affiliations

Soon will be listed here.

Abstract

Amphotericin B (AmB) is an effective and commonly used antifungal agent. However, nephrotoxicity and poor solubility limits its usage. The proposed polymerized cyclodextrin (pCD) system therefore is an attractive method for AmB delivery, as it retains the antifungal activity of AmB while decreasing toxicity, and confining drug release to the local environment. This system could potentially be used for both prevention and treatment of established fungal infections, as AmB is toxic to fungus whether associated or released from pCD.

Citing Articles

Lidocaine-Liposomes-A Promising Frontier for Transdermal Pain Management.

Leon M, Mastaleru A, Oancea A, Alexa-Stratulat T, Peptu C, Tamba B J Clin Med. 2024; 13(1).

PMID: 38202278 PMC: 10779996. DOI: 10.3390/jcm13010271.

Controlled delivery of a protein tyrosine phosphatase inhibitor, SHP099, using cyclodextrin-mediated host-guest interactions in polyelectrolyte multilayer films for cancer therapy.

Wang S, Battigelli A, Alkekhia D, Fairman A, Antoci V, Yang W RSC Adv. 2022; 10(34):20073-20082.

PMID: 35520441 PMC: 9054207. DOI: 10.1039/d0ra03864d.

Research Progress on Synthesis and Application of Cyclodextrin Polymers.

Liu Y, Lin T, Cheng C, Wang Q, Lin S, Liu C Molecules. 2021; 26(4).

PMID: 33669556 PMC: 7922926. DOI: 10.3390/molecules26041090.

Periadventitial Delivery of Simvastatin-Loaded Microparticles Attenuate Venous Neointimal Hyperplasia Associated With Arteriovenous Fistula.

Zhao C, Zuckerman S, Cai C, Kilari S, Singh A, Simeon M J Am Heart Assoc. 2020; 9(24):e018418.

PMID: 33283594 PMC: 7955373. DOI: 10.1161/JAHA.120.018418.

Affinity-Based Polymers Provide Long-Term Immunotherapeutic Drug Delivery Across Particle Size Ranges Optimal for Macrophage Targeting.

Rohner N, Purdue L, von Recum H J Pharm Sci. 2020; 110(4):1693-1700.

PMID: 33127427 PMC: 8989363. DOI: 10.1016/j.xphs.2020.10.046.

References

Singh N . Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis. 2001; 33(10):1692-6. DOI: 10.1086/323895. View

Sanchez-Brunete J, Dea M, Rama S, Bolas F, Alunda J, Raposo R . Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrob Agents Chemother. 2004; 48(9):3246-52. PMC: 514726. DOI: 10.1128/AAC.48.9.3246-3252.2004. View

Davis M, Brewster M . Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov. 2004; 3(12):1023-35. DOI: 10.1038/nrd1576. View

Lincopan N, Mamizuka E, Carmona-Ribeiro A . Low nephrotoxicity of an effective amphotericin B formulation with cationic bilayer fragments. J Antimicrob Chemother. 2005; 55(5):727-34. DOI: 10.1093/jac/dki064. View

Raychaudhuri R, Yu W, Hatanpaa K, Cavuoti D, Pride G, White J . Basilar artery dissection treated by Neuroform stenting: fungal stent infection. Surg Neurol. 2008; 71(4):477-80. DOI: 10.1016/j.surneu.2007.11.022. View

Dufour G, Montravers P . Pharmacokinetics of antibiotics or antifungal drugs in intensive care units. Curr Infect Dis Rep. 2008; 11(1):14-20. DOI: 10.1007/s11908-009-0003-9. View

Chakraborty K, Naik S . PHARMACOKINETIC STUDIES OF IN-SITU LIPOSOMAL PREPARATION CONTAINING AMPHOTERICIN B COMPLEXED WITH DIFFERENT CHEMICALLY MODIFIED beta-CYCLODEXTRINS. J Liposome Res. 2009; 11(1):1-14. DOI: 10.1081/LPR-100103166. View

Thatiparti T, von Recum H . Cyclodextrin complexation for affinity-based antibiotic delivery. Macromol Biosci. 2009; 10(1):82-90. DOI: 10.1002/mabi.200900204. View

Shimizu K, Osada M, Takemoto K, Yamamoto Y, Asai T, Oku N . Temperature-dependent transfer of amphotericin B from liposomal membrane of AmBisome to fungal cell membrane. J Control Release. 2009; 141(2):208-15. DOI: 10.1016/j.jconrel.2009.09.019. View

10.

Thatiparti T, Shoffstall A, von Recum H . Cyclodextrin-based device coatings for affinity-based release of antibiotics. Biomaterials. 2009; 31(8):2335-47. DOI: 10.1016/j.biomaterials.2009.11.087. View

11.

Wang N, von Recum H . Affinity-based drug delivery. Macromol Biosci. 2010; 11(3):321-32. DOI: 10.1002/mabi.201000206. View

12.

Fu A, Thatiparti T, Saidel G, von Recum H . Experimental studies and modeling of drug release from a tunable affinity-based drug delivery platform. Ann Biomed Eng. 2011; 39(9):2466-75. DOI: 10.1007/s10439-011-0336-z. View

13.

Ramage G, Jose A, Sherry L, Lappin D, Jones B, Williams C . Liposomal amphotericin B displays rapid dose-dependent activity against Candida albicans biofilms. Antimicrob Agents Chemother. 2013; 57(5):2369-71. PMC: 3632906. DOI: 10.1128/AAC.02344-12. View

14.

Mishra J, Dey A, Singh N, Somvanshi R, Singh S . Evaluation of toxicity & therapeutic efficacy of a new liposomal formulation of amphotericin B in a mouse model. Indian J Med Res. 2013; 137(4):767-76. PMC: 3724259. View

15.

Wade R, Chaudhari P, Natoli J, Taylor R, Nathanson B, Horn D . Comparison of adverse events and hospital length of stay associated with various amphotericin B formulations: sequential conventional amphotericin b/lipid versus lipid-only therapy for the treatment of invasive fungal infections in hospitalized.... P T. 2013; 38(5):278-87. PMC: 3737979. View

16.

Kawila R, Chaiwarith R, Supparatpinyo K . Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study. BMC Infect Dis. 2013; 13:464. PMC: 3851520. DOI: 10.1186/1471-2334-13-464. View

17.

Robledo-Avila F, Perez-Tapia M, Limon-Flores A, Pavon L, Hernandez-Pando R, Wong-Baeza I . Low-dose amphotericin B and murine dialyzable spleen extracts protect against systemic candida infection in mice. Clin Dev Immunol. 2013; 2013:194064. PMC: 3782815. DOI: 10.1155/2013/194064. View

18.

Vincent B, Lancaster A, Scherz-Shouval R, Whitesell L, Lindquist S . Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol. 2013; 11(10):e1001692. PMC: 3812114. DOI: 10.1371/journal.pbio.1001692. View

19.

Halpern J, Gormley C, Keech M, von Recum H . Thermomechanical Properties, Antibiotic Release, and Bioactivity of a Sterilized Cyclodextrin Drug Delivery System. J Mater Chem B. 2014; 2(18):2764-2772. PMC: 4058863. DOI: 10.1039/C4TB00083H. View

20.

Suleyman G, Alangaden G . Nosocomial Fungal Infections: Epidemiology, Infection Control, and Prevention. Infect Dis Clin North Am. 2016; 30(4):1023-1052. DOI: 10.1016/j.idc.2016.07.008. View